Bayer to license lipid-nanoparticle tech from Acuitas

07 Jun 2023
www.pharmamanufacturing.com
VaccinemRNAGene TherapyLicense out/in
Bayer, looking to enhance its gene editing program, will partner with Acuitas Therapeutics on the development of lipid-nanoparticle systems for molecular therapeutics.
Canada-based Acuitas' clinically validated LNP delivery technology enables the targeted delivery of ribonucleic acids (RNA) to the liver. The proprietary technology was also used to develop the Pfizer-BioNTech COVID-19 vaccineCOVID-19 vaccine.
In addition to mRNA, AcuitasAcuitas' LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA.
Bayer, through its gene therapy unit, AskBio, hopes that the partnership will help accelerate its first in vivo gene editing programs to the clinic. Bayer paid $2 billion upfront back in 2020 in a deal that focused on AskBio’s industry-leading AAV-based gene therapy platform.
Financial details of the Acuitas deal were not disclosed.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.